Last10K.com

Unum Therapeutics Inc. (UMRX) SEC Filing 8-K Material Event for the period ending Wednesday, January 29, 2020

Unum Therapeutics Inc.

CIK: 1622229 Ticker: UMRX

View differences made from one to another to evaluate Unum Therapeutics Inc.'s financial trajectory

Compare SEC Filings Year-over-Year (YoY) and Quarter-over-Quarter (QoQ)
Sample 10-K Year-over-Year (YoY) Comparison

Compare this 8-K Corporate News to its predecessor by reading our highlights to see what text and tables were  removed  ,   added    and   changed   by Unum Therapeutics Inc..

Continue

Assess how Unum Therapeutics Inc.'s management team is paid from their Annual Proxy

Definitive Proxy Statement (Form DEF 14A)
Screenshot example of actual Proxy Statement

Unum Therapeutics Inc.'s Definitive Proxy Statement (Form DEF 14A) filed after their 2020 10-K Annual Report includes:

  • Voting Procedures
  • Board Members
  • Executive Team
  • Salaries, Bonuses, Perks
  • Peers / Competitors

Continue

SEC Filing Tools

Material Contracts, Statements, Certifications & more

Unum Therapeutics Inc. provided additional information to their SEC Filing as exhibits

Ticker: UMRX
CIK: 1622229
Form Type: 8-K Corporate News
Accession Number: 0001193125-20-017633
Submitted to the SEC: Wed Jan 29 2020 7:13:02 AM EST
Accepted by the SEC: Wed Jan 29 2020
Period: Wednesday, January 29, 2020
Industry: Pharmaceutical Preparations
Events:
  1. Financial Exhibit
  2. Other Events

External Resources:
Stock Quote
Social Media
SEC.gov

Bookmark the Permalink:
https://last10k.com/sec-filings/umrx/0001193125-20-017633.htm